June 29, 2016June 29, 2016

PH Associated Idiopathic Interstitial Pneumonias: EMA Says ‘No’ to Adempas (Riociguat)

The European Medicines Agency (EMA) has recommended against Adempas (riociguat) for patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP), according to a recent press release. EMA’s recommendation follows Bayer Pharmaceuticals‘ announcement in May for ... Read more

May 24, 2016May 24, 2016

Bayer Ends Phase 2 Trial of Riociguat in PH Patients with Idiopathic Interstitial Pneumonias

News, Pulmonary Hypertension

Bayer has stopped a Phase 2 clinical trial (NCT02138825) evaluating riociguat (Adempas) in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) on the recommendation of the study’s Data Monitoring Committee (DMC). The committee — sometimes ... Read more